Literature DB >> 12792729

Clinical experience of ureteroscopic treatment for ureteral transitional cell carcinoma using the Holmium:YAG laser.

Yoshiaki Yamada1, Nobuaki Honda, Kogenta Nakamura, Hatsuki Hibi, Hiroshi Nanaura, Eiji Nishikawa, Ayumi Kamijou, Kenji Mitsui, Tomohiro Taki, Shigeyuki Aoki, Hiroto Kokubo, Hidetoshi Fukatsu.   

Abstract

The standard operative method for ureteral transitional cell carcinoma is nephrouterectomy with partial bladder excision of the ureteral orifice of the affected bladder. However, a conservative kidney operation and endoscopy are now being performed for low grade, low stage cases. We performed an operation using a Holmium: YAG laser, and examined its safety and efficacy. The patients were four men, and 1 woman aged from 68 to 87 (mean 78) years. There were 2 imperative cases (1 solitary kidney case, and 1 high-risk case), and 3 elective cases. The tumor size ranged from 8 to 25 (mean 14) mm. Urinary cytology was negative in all cases, and the tumors were pathologically diagnosed as grade 1 atypism on biopsy. A VersaPulse Select 80 laser generator, a 365 micro m SlimLine laser fiber, and an 8F rigid ureteroscope were used. A 6F double J catheter was indwelt for three weeks after the surgery. The pulse energy setting was 0.5-1.0 J, and the frequency was 10 Hz. The total amount of energy was 1.02-11.22 (mean 3.56) kJ, and the operation time was 20-97 (mean 50) min including the time for indwelling a ureteral stent. Neither urinary tract perforation nor ureteral stricture caused by the laser irradiation were observed. The patients have been followed by examining urine cytology once a month, and cystoscopy, retrograde pyelography, and urethroscopy once every 3 months. No recurrence has been observed as of 4-20 (mean 10) months postoperatively. Transurethral endoscopic resection using a Holmium: YAG laser is a safe and effective therapy for ureteral transitional cell carcinoma while preserving kidney and a good treatment outcome can be expected even in elective cases.

Entities:  

Mesh:

Year:  2003        PMID: 12792729

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

Review 1.  Endoscopic Treatment of Upper Tract Urothelial Carcinoma.

Authors:  Daniel P Verges; Costas D Lallas; Scott G Hubosky; Demetrius H Bagley
Journal:  Curr Urol Rep       Date:  2017-04       Impact factor: 3.092

Review 2.  Lasers in the upper urinary tract for non-stone disease.

Authors:  Courtney K Phillips; Jaime Landman
Journal:  World J Urol       Date:  2007-06-12       Impact factor: 3.661

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.